Pcas: Net sales as of June 30, 2023
27 Juillet 2023 - 6:00PM
Pcas: Net sales as of June 30, 2023
Ecully, July 27, 2023
NET SALES AS OF
JUNE 30,
2023
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as of June 30, 2023.
The PCAS Group has generated consolidated net
sales of €113.4 million as of June 30, 2023, a 3.3% increase
compared to the same period during the previous financial year
(+2.9% at constant exchange rates).
In millions of euros |
|
2023 |
|
2022 |
|
% change |
|
2023 At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
Sales
as of 30 June |
|
113.4 |
|
109.8 |
|
3.3% |
|
113.0 |
|
2.9% |
Pharmaceutical
Synthesis |
|
68.8 |
|
67.4 |
|
2.0% |
|
68.6 |
|
1.7% |
Fine Specialty Chemicals |
|
44.7 |
|
42.4 |
|
5.4% |
|
44.4 |
|
4.7% |
in millions of euros |
France |
Other areas |
Total |
|
|
|
|
Net Sales
by origin |
|
|
|
June 30,
2023 |
80.0 |
33.4 |
113.4 |
June 30,
2022 |
84.6 |
25.2 |
109.8 |
|
|
|
|
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business generated
sales of €68.8 million, a 2.0% increase compared to 2022 (a 1.7%
increase at a constant exchange rate). Adjusted for Estetrol, this
growth came to +35.3% (+35.0% at constant exchange rates), mainly
as a result of a strong activity at the Turku and Aramon sites, as
well as higher demand for R&D services. Sales also benefited
from the price increases implemented during the course of 2022.
Fine Specialty Chemicals
Net sales of Specialty Fine Chemicals totaled
€44.7 million, a 5.4% increase compared to 2022 (a 4.7% increase at
constant exchange rates). Excluding sales of June 2022 of the
Canadian subsidiary which was disposed at the beginning of June
2023, the increase is 11.0% (a 10.2% increase at constant exchange
rates). Demand was generally good at the start of the year, with
however a slowdown in the Lubricants business, offset by the
dynamism of other activities and the effects of price increases
implemented during the course of 2022.
Outlook
In the context of the ongoing dispute with the
customer Mithra, a temporary shutdown has been implemented during
the second quarter of 2023 at the production site concerned, some
of whose workshops are dedicated to the production of Estetrol. At
this stage, it is still not possible to accurately assess the
consequences of this dispute on future sales and earnings.
The sale of the Group's Canadian subsidiary at
the beginning of June 2023 enabled to repay part of Seqens' current
account debt and generated a significant capital gain, enabling
PCAS to rebuild its shareholders' equity and generate positive net
income. However, the PCAS Group's current operating income is
likely to remain in deficit, and as indicated in the press releases
of March 30 and April 24, 2023, the return to positive results,
previously announced for 2023, has been postponed.
PCAS Group will continue to benefit from the
support of its majority shareholder Seqens (owning 76.66%) for the
financing of its activities and its development.
NEXT FINANCIAL DISCLOSURE:
Results of the first semester 2023 – September 6,
2023
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With about 11% of its net sales earmarked for R&D
and a large international footprint, PCAS is the preferred
industrial partner for market-leading major global groups. Boasting
especially high standards, the company offers a growing range of
proprietary products and solutions in leading-edge segments. PCAS
generated net sales of €226.4 million in 2022 and employs nearly
1200 people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
NewCap |
Jean-Louis Martin / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier Financial
communication and investor relation |
|
|
Tel.: +33 1 69 79 60 00www.pcas.com |
Tel.: +33 1 44 71 98 53pcas@newcap.eu |
|
|
- PCAS_PR_H1 2023 Sales _ENG
PCAS (EU:PCA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
PCAS (EU:PCA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024